New hope for bladder cancer patients: radiotherapy trial aims to improve survival and quality of life
NCT ID NCT07524426
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase III trial tests whether adding local radiotherapy to standard care helps bladder cancer patients who are not eligible for curative treatment live longer and feel better. About 248 participants will be randomly assigned to receive either standard care alone or standard care plus modern, targeted radiotherapy. The study also collects biomarkers to personalize future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Local hypofractionated adaptive radiotherapy
- What this could lead to
- If successful, this could offer a well-tolerated treatment option that extends survival and improves quality of life for bladder cancer patients who cannot have curative therapy.
- What could go wrong
- This is an early-stage trial with 248 participants, so results may not apply to all patients. Radiotherapy can cause side effects like bladder irritation or fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER (BC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Norrlands University Hosital
RECRUITINGUmeå, Västerbotten County, 90185, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.